Skip to main
ROIV

ROIV Stock Forecast & Price Target

ROIV Analyst Ratings

Based on 10 analyst ratings
Buy
Strong Buy 60%
Buy 30%
Hold 10%
Sell 0%
Strong Sell 0%

Bulls say

Roivant Sciences is a promising biopharmaceutical company with a strong pipeline of drug candidates in various stages of development. Their recently started Phase 3 study for brepocitinib has the potential to be successful, given the positive results seen in their Phase 2 study. The company's other drug candidates, such as IMVT-1402, also show promising potential for various rare diseases. While potential risks include regulatory and commercial challenges, Roivant's innovative approach and potential partnerships could help mitigate these risks.

Bears say

Roivant Sciences is experiencing a negative outlook due to declining revenues, increasing losses, and substantial growth in R&D and SG&A expenses. This trend is likely to continue due to the higher program-specific spending and personnel-related expenses related to their drug candidates, resulting in a downward trend in their financial performance. Furthermore, with $3.9B in cash reserves, it is uncertain if Roivant Sciences will be able to achieve profitability in the near future.

ROIV has been analyzed by 10 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 30% recommend Buy, 10% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Roivant Sciences Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Roivant Sciences Ltd (ROIV) Forecast

Analysts have given ROIV a Buy based on their latest research and market trends.

According to 10 analysts, ROIV has a Buy consensus rating as of Aug 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Roivant Sciences Ltd (ROIV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.